WHO Pharmaceuticals Newsletter 2003, No. 04
(2003; 13 pages) View the PDF document
Table of Contents
Open this folder and view contentsREGULATORY MATTERS
Close this folderSAFETY OF MEDICINES
View the documentATYPICAL ANTI-PSYCHOTICS - Reports of hypertension
View the documentBOTULINUM A - Patients misled over safety
View the documentCHELIDONIUM MAJUS - Statement to advise use under supervision
View the documentCYCLO-OXYGENASE (COX)-2 INHIBITORS - Reports of hepatotoxicity
View the documentETONOGESTREL - Vaginal bleeding with sub-dermal implant
View the documentFLUTICASONE - ADR update
View the documentGATIFLOXACIN - Reports of abnormal glucose metabolism
View the documentHORMONE REPLACEMENT THERAPY (HRT) - ‘Million Women Study’ confirms breast cancer association
View the documentMEDROXY-PROGESTERONE - Reports of contraception failure with depot preparations
View the documentMEFLOQUINE - Patient guide warns of psychiatric adverse events
View the documentMETHOTREXATE - New solutions to prevent fatalities/adverse events
View the documentMINOCYCLINE - Hepatic reactions
View the documentPIPERACILLIN - Serum methotrexate monitoring advised during concomitant therapy
View the documentRIFAMPICIN & PYRAZINAMIDE - Warning against use in latent tuberculosis
View the documentSELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs): Reports of hyponatraemia
View the documentSIBUTRAMINE - Serotonin syndrome
View the documentTICLOPIDINE - No decrease in ADR reports
View the documentVIGA/VIGA FOR WOMEN - Presence of sildenafil
View the documentWARFARIN & MICONAZOLE - Reminder about interaction
Open this folder and view contentsDRUGS IN THE NEWS
 

VIGA/VIGA FOR WOMEN - Presence of sildenafil

USA. Health Nutrition (RMA Laboratories), under advice from the US FDA is warning consumers not to purchase or consume the product known as VIGA or VIGA FOR WOMEN. These products are sold as dietary supplements, without a medical prescription and have been found to contain sildenafil. Sildenafil is a prescription drug and may have serious health risks if used without medical supervision, particularly if the users are also on concurrent nitrate therapy. The interaction between nitrates and sildenafil can result in profound and life-threatening lowering of blood pressure. The use of nitrates is therefore an absolute contraindication for sildenafil users. Consumers who have purchased VIGA or VIGA FOR WOMEN tablets are urged to immediately discontinue their use and to return them to their place of purchase or directly to Health Nutrition (RMA Laboratories).

Reference:

Recall-Firm Press Release from Health Nutrition, 24 Jun 2003. Available from URL: http://www.fda.gov

to previous section to next section
 

Last updated: May 3, 2013